Tetomilast

Drug Profile

Tetomilast

Alternative Names: OPC-6535

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Anti-inflammatories; Anti-ischaemics; Carboxylic acids; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • Discontinued Crohn's disease; Heart failure; Reperfusion injury; Ulcerative colitis

Most Recent Events

  • 09 Sep 2015 Phase-II development is ongoing for Chronic obstructive pulmonary disease in Japan, US and Asia
  • 07 Aug 2015 Otsuka terminates phase II trial in Chronic obstructive pulmonary disorders in USA (NCT00874497)
  • 01 Apr 2014 Otsuka Pharmaceutical completes a phase II in Chronic obstructive pulmonary disease in Japan, China, and South Korea (NCT00917150)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top